 PerkinElmer Acquisition of ViaCell Exhibit 99.1 |
 Page 2 Factors Affecting Future Performance Statements in this presentation regarding the proposed transaction between PerkinElmer and ViaCell, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities and expansion for the combined company, the expected impact of the anticipated transaction on PerkinElmer’s earnings, the extent to which the transaction advances PerkinElmer’s business, expectations for growth of the family cord blood banking market and the ViaCord business, the advancement of ViaCell’s product candidates and plans for ViaCell’s therapeutic and research businesses, and any other statements about PerkinElmer or ViaCell managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the possibility that certain closing conditions to the transaction will not be met; the ability to consummate the transaction, the ability of PerkinElmer to successfully integrate ViaCell’s operations and employees; the ability to realize anticipated synergies and cost savings; and the other factors described in PerkinElmer���s Annual Report on Form 10-K for the year ended December 31, 2006 and in ViaCell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each of which has been filed with the SEC. Except as otherwise required by law, PerkinElmer and ViaCell disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. |
 Page 3 An industry leader in the preservation of umbilical cord blood stem cells with therapeutic pipeline Headquartered in Cambridge, MA, with processing center in Hebron, KY 280 total employees Mid-to-high $60 mil rev range in 2007; historical growth of 20%+ annually Greater than 130,000 customers Experienced U.S. sales and marketing team Track record of transplant success ViaCell Overview |
 Page 4 2000 2006 Potential market 30% of 4 mm U.S. births $20 million $160 million $1.4 billion Diseases Treatable by Cord Blood Number of Cord Blood Transplants Number of Family Cord Blood Units Banked Cumulative Incidence Rate of Disease Treatable with Cord Blood Stem Cells 1988 1 1 0 1 in 300,000 + 2006 40 8,000 400,000 1 in 100 Cord blood banking market growth… …driven by expansion of diseases treatable with cord blood |
 Page 5 40 Diseases Treatable Today Cancers Bone Marrow Failure Blood Disorders Metabolic Disorders Immunodeficiencies Other Diseases ALL AML Burkitt lymphoma CML JCML Non-Hodgkin Hodgkin’s Langerhans’ cell histiocytosis JMML Liposarcoma MDS CMML Neuoblastoma Severe aplastic anemia Diamond-blackfan anemia Dyskeratosis Congenita Fanconi anemia Amegakaryocytic thrombocytopenia Kostmann’s syndrome Sickle-Cell Anemia Adrenoleukodystrophy Batten disease Gunther disease Hunter syndrome Hurler syndrome Krabbe disease Lesch-Nyhan disease Maroteaux-Lamy syndrome Beta-Thalassemia Omenn’s syndrome SCID Reticular Dysplasia Thymic Dysplasia Wiskott-Aldrich syndrome X-linked lymphoproliferative Leukemia adhesion deficiency Evan’s syndrome Familial hemophagocytic lymphohistiocytosis EBV=assoc. amogakaryotic lymphohistiocytosis Osteopetrosis Many significant diseases… …are treatable with cord blood |
     Page 6 Experienced Sales and Marketing team…. Physician Focus 55 Field Sales Reps Patient Focus 50 Inside Sales Reps • Dedicated OB/GYN sales group • Physician education • Specialized training programs • Dedicated telesales group • Mothers Work contract • Direct Mail, Web and Media ….developing consumer and clinical channels |
 Page 7 PerkinElmer and ViaCell combine to… World leader in neonatal genetic screening…ability to screen for over 50 disorders Global leader in first trimester prenatal genetic screening Proprietary markers for pregnancy related disorders in development Emerging Cytogenetic/Mol Dx capabilities Global reach…sales channel and research network A leader in umbilical cord stem cell preservation…indicated for over 40 treatable diseases Strong OB/GYN sales and marketing organization Well established presence in the direct-to-patient marketing channel …strengthen global leadership in newborn health |
 Page 8 Genetic screening focused on healthy mothers and babies… …multiple touch points and tests Preconception Prenatal / Maternal Childhood Neonatal Est. Market Potential ~$0.5B ~$1B+ ~$1B+ ~$0.5B PKI Capabilities Tools x x x x Content x (future) x x x (future) Service x x Market CAGR 15-20% |
 Page 9 Offer testing to banking families Stem cell banking CGHa (Spectral) MDx International Neonatal Prenatal Market Leverage global structure 0% 55% revenue internationally (Genetic Screening) Test for more disorders Direct-to-consumer marketing (50 inside sales) 50+ disorders 29 standard of care Increase % of pregnancies captured 55 reps 10 reps (NTD) capture 300k pregnancies Opportunity Significant synergies… …across all markets |
 Page 10 Significant opportunity to expand market penetration… % captured pregnancies/newborns …and add value per pregnancy $1000+ $10 $100 50% 100% Today …multiple touch points preconception to early childhood …multiple tests pre-eclampsia, preterm birth, IUGR …screen, diagnose, monitor/treat LSD screen, Krabbe diagnose, stem cell transplant Goal |
 Page 11 Financial rationale for acquisition of ViaCell… Transaction Consideration – $7.25 per share in cash ($260 mil net cash) Valuation – 3.9x 2007E revenue (analyst consensus estimate $67 mil) • 80%+ gross margins • 20%+ operating margin potential Financial Impact to Adjusted EPS * – $0.01 dilutive in Q4’07 $0.03 – $0.05 dilutive in 2008 $0.02 – $0.03 accretive in 2009 Financing – Existing cash on hand, borrowings under credit facility and other borrowings being evaluated Closing – Fourth quarter of 2007, assuming successful completion of tender offer, customary closing conditions and antitrust clearance …driven by growth profile and added scale * Adjusted EPS excludes discontinued operations, amortization of intangible assets, inventory fair value adjustments, in-process research and development charges, deferred revenue adjustments and other significant adjustments related to business acquisitions, gains on settlement of insurance claim, restructuring and lease charges, stock option expense and certain other gains and losses. |
 Page 12 ViaCell acquisition strengthens leadership position… Adds attractive growth leg Sales/marketing channel synergies • OB/GYN • Consumer • International Increases opportunities for additional testing • Neonatal • Molecular Diagnostics Additional opportunities • Long term customer relationship • Additional products through channel 2007 Combined Est. 2010 Forecast $260-270M $500M+ Acq $100 VIAC PKI $425-475M 15-20% Organic Growth Genetic Screening Revenue …and increases potential for long term growth |
 Page 13 Important Additional Information Will Be Filed with the Securities Exchange Commission (SEC) This document is neither an offer to purchase nor a solicitation of an offer to sell shares of ViaCell, Inc. PerkinElmer has not commenced the tender offer for shares of ViaCell stock described in this document. At the time the tender offer is commenced, PerkinElmer will file with the SEC and mail to ViaCell’s stockholders a Tender Offer Statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal and other related documents, and ViaCell will file with the SEC and mail to its stockholders a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 in connection with the transaction. These will contain important information about PerkinElmer, ViaCell, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available. Investors and security holders will be able to obtain free copies of the Tender Offer Statement, the Tender Offer Solicitation/Recommendation Statement and other documents filed with the SEC by PerkinElmer and ViaCell through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents by contacting the Investor Relations departments of PerkinElmer or ViaCell. |
 Page 14 |